Licensed sports products company Dreams, Inc. (DRJ) announced a partnership with the NBA's Washington Wizards. Under the deal Dreams will launch the team's official online store. Dreams shares surged 30% Friday morning.
Shares of wireless networking company Aruba Networks (NASDAQ:ARUN) gained about 17 and a half percent after the company reported record revenues for the quarter, and a smaller net loss of 5 cents per share. In the same quarter last year, the company lost 8 cents per share.
Facet Biotech (FACT) and Trubion Pharmaceuticals (TRBN) announced a joint development and commercialization agreement, for a drug candidate currently in phase 1 clinical development, to treat chronic lymphocytic leukemia. Trubion will receive an upfront payment of 20 million dollars, and may earn up to 176.5 million in milestone payments. Facet will also purchase about 2.2 million common shares of Trubion for 10 million dollars. Trubion shares rocketed over 58% higher in early trading Friday.
And Sinovac Biotech (NASDAQ:SVA) announced it was selected by the Beijing Public Health Bureau to supply its seasonal influenza vaccine, Anflu. Under the Bureau's plan, elementary and secondary school students as well as people over age 60 would receive the vaccine at no charge, reaching an estimated 2.8 million citizens in Beijing. Sinovac shares advanced 13% early Friday.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.